-
1.发明授权Methods for prevention and treatment of inflammation using anti-chemokine antibodies 有权使用抗趋化因子抗体预防和治疗炎症的方法公开(公告)号：US08580261B2
公开(公告)日：2013-11-12
申请号：US13538355
申请日：2012-06-29
Applicant: James W. Lillard, Jr. , Udai P. Singh , Shailesh Singh , Jonathan Stiles
Inventor： James W. Lillard, Jr. , Udai P. Singh , Shailesh Singh , Jonathan Stiles
IPC: A61K39/00 , A61K39/395
CPC classification number: C07K16/24 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/2866 , C07K16/2896 , C07K2317/76 , C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N2333/521
Abstract: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.
Abstract translation: 可以通过给予趋化因子的抗体来抑制炎症过程。 鉴定过度生成的趋化因子使得可以使用针对过度表达的趋化因子的抗体来阻断特异性趋化因子活性。
-
2.发明授权公开(公告)号：US08541564B2
公开(公告)日：2013-09-24
申请号：US13480526
申请日：2012-05-25
Applicant: James W. Lillard, Jr.
Inventor： James W. Lillard, Jr.
CPC classification number: C07K16/2866 , A61K38/00 , C07K14/521 , C07K2319/30 , Y02A50/401
Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.
-
3.发明申请DELIVERY SYSTEM FOR SPECIFICALLY TARGETING CANCER CELLS AND METHOD OF USE THEREOF 审中-公开用于特异性靶向癌细胞的递送系统及其使用方法公开(公告)号：US20130045162A1
公开(公告)日：2013-02-21
申请号：US13569941
申请日：2012-08-08
Applicant: James W. Lillard, JR. , Shailesh Singh , Rajesh Singh
Inventor： James W. Lillard, JR. , Shailesh Singh , Rajesh Singh
IPC: A61K9/14 , A61K51/12 , A61K39/395 , A61K31/7088 , A61K38/02 , A61K39/05 , A61K39/104 , A61K39/00 , A61K31/522 , A61K31/352 , A61K38/47 , A61K31/282 , A61K33/24 , A61K31/337 , A61P35/00 , A61P35/04 , A61P35/02 , A61K31/12 , B82Y5/00
CPC classification number: A61K31/282 , A61K31/337 , A61K31/365 , A61K38/00 , A61K47/551 , A61K47/6935
Abstract: Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of tumor associated antigen binding ligand-coated planetary ball milled (PBM) nanoparticles containing a cytotoxic agent.
Abstract translation: 公开了预防，治疗或抑制受试者中癌细胞生长或转移的方法。 一种方法包括向受试者施用治疗有效量的含有细胞毒性剂的肿瘤相关抗原结合配体的行星球磨（PBM）纳米颗粒的步骤。
-
4.发明申请ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR INFLAMMATORY DISORDERS 有权ANTI-CXCL9，ANTI-CXCL10，ANTI-CXCL11，ANTI-CXCL13，ANTI-CXCR3和抗CXCR5抗炎药物公开(公告)号：US20120264645A1
公开(公告)日：2012-10-18
申请号：US13535215
申请日：2012-06-27
Applicant: James W. Lillard, JR.
Inventor： James W. Lillard, JR.
IPC: G01N33/566 , C40B40/10 , C40B30/04 , C12Q1/68 , G01N21/64
CPC classification number: C07K16/24 , A61K2039/505 , C07K16/2866
Abstract: A method for detecting an inflammatory disease in a subject is disclosed. The method comprises the steps of (a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from the subject; and (b) comparing the level of expression of said one or more inflammatory disease markers in the biological sample to a normal level of expression of the one or more inflammatory disease markers, wherein the one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5. Also disclosed are a method for monitoring the course of treatment for an inflammatory disease in a subject and a kit for detecting an inflammatory disease in a subject.
Abstract translation: 公开了一种用于检测受试者的炎性疾病的方法。 该方法包括以下步骤：（a）检测从受试者获得的生物样品中的一种或多种炎性疾病标志物的表达水平; 和（b）将生物样品中所述一种或多种炎性疾病标志物的表达水平与一种或多种炎症性疾病标志物的正常表达水平进行比较，其中所述一种或多种炎症性疾病标志物包括选择的一种或多种标志物 来自CXCL9，CXCL10，CXCL11，CXCL13，CXCR3和CXCR5。 还公开了一种用于监测受试者的炎性疾病的治疗过程的方法和用于检测受试者的炎性疾病的试剂盒。
-
公开(公告)号：US6153182A
公开(公告)日：2000-11-28
申请号：US213878
申请日：1998-12-17
Applicant: James W. Lillard, Jr.
Inventor： James W. Lillard, Jr.
CPC classification number: C07K14/52 , A61K39/39 , A61K2039/541 , A61K2039/55522 , A61K38/00 , A61K39/00 , Y10S514/885
Abstract: Compositions of lymphotactin in cellular immune enhancing amounts may advantageously be administered at very low levels in conjunction with vaccines to provide improved immune response, Suggested dosage such as 1 to 10 .eta.g in small animals and from 10 .mu.g to 10 mg in large mammals may be administered.
Abstract translation: 细胞免疫增强量中淋巴细胞趋化因子的组合物可以有利地与疫苗结合非常低的水平施用，以提供改善的免疫应答。建议的剂量，例如小动物中的1-10分，和大型哺乳动物中的10μg至10mg 被管理。
-
Patent Agency Ranking
6.发明授权Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms 有权用于抑制肿瘤生长的抗趋化因子和相关受体抗体公开(公告)号：US07919083B2
公开(公告)日：2011-04-05
申请号：US10712398
申请日：2003-11-14
Applicant: James W. Lillard, Jr. , Pier Nicole Hannah , Shailesh Singh , Jonathan K. Stiles
Inventor： James W. Lillard, Jr. , Pier Nicole Hannah , Shailesh Singh , Jonathan K. Stiles
IPC: A61K39/395
CPC classification number: A61K39/3955 , C07K16/24 , C07K16/2866 , C07K2317/73
Abstract: The present invention provides a means of inhibiting the growth and metastasis of cancer cells by administering anti-chemokine antibodies. It is possible to identify the particular chemokines which are over-expressed in the tumor using methods of the invention and administer antibodies against that over-expressed chemokine.
Abstract translation: 本发明提供了通过施用抗趋化因子抗体来抑制癌细胞的生长和转移的方法。 可以使用本发明的方法鉴定在肿瘤中过表达的特定趋化因子，并且针对该过度表达的趋化因子施用抗体。
-
7.发明授权Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders 有权抗CXCL9，抗CXCL10，抗CXCL11，抗CXCL13，抗CXCR3和抗CXCR5用于炎性疾病的药物公开(公告)号：US08563476B2
公开(公告)日：2013-10-22
申请号：US13535215
申请日：2012-06-27
Applicant: James W. Lillard, Jr.
Inventor： James W. Lillard, Jr.
IPC: A61K39/00 , A61K39/395 , C40B30/04 , C40B40/10 , G01N33/53 , C12Q1/68 , G01N33/566
CPC classification number: C07K16/24 , A61K2039/505 , C07K16/2866
Abstract: A method for detecting an inflammatory disease in a subject is disclosed. The method comprises the steps of (a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from the subject; and (b) comparing the level of expression of said one or more inflammatory disease markers in the biological sample to a normal level of expression of the one or more inflammatory disease markers, wherein the one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5. Also disclosed are a method for monitoring the course of treatment for an inflammatory disease in a subject and a kit for detecting an inflammatory disease in a subject.
Abstract translation: 公开了一种用于检测受试者的炎性疾病的方法。 该方法包括以下步骤：（a）检测从受试者获得的生物样品中的一种或多种炎性疾病标志物的表达水平; 和（b）将生物样品中所述一种或多种炎性疾病标志物的表达水平与一种或多种炎症性疾病标志物的正常水平的表达进行比较，其中所述一种或多种炎性疾病标志物包括选择的一种或多种标志物 来自CXCL9，CXCL10，CXCL11，CXCL13，CXCR3和CXCR5。 还公开了一种用于监测受试者的炎性疾病的治疗过程的方法和用于检测受试者的炎性疾病的试剂盒。
-
8.发明申请CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, METHOD OF MAKING AND USE THEREOF 有权化合物 - 免疫球蛋白融合多肽，组合物，制备和使用方法公开(公告)号：US20120308565A1
公开(公告)日：2012-12-06
申请号：US13480526
申请日：2012-05-25
Applicant: James W. Lillard, JR.
Inventor： James W. Lillard, JR.
CPC classification number: C07K16/2866 , A61K38/00 , C07K14/521 , C07K2319/30 , Y02A50/401
Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.
Abstract translation: 本申请涉及趋化因子 - 免疫球蛋白融合多肽和趋化因子 - 聚合物缀合物。 融合多肽和缀合物可用于治疗趋化因子受体介导的紊乱并调节炎症，炎性细胞运动，癌细胞运动或癌细胞存活。
-
公开(公告)号：US20110287063A1
公开(公告)日：2011-11-24
申请号：US13104654
申请日：2011-05-10
Applicant: James W. Lillard, JR. , Udai P. Singh , Shailesh Singh , Jonathan K. Stiles
Inventor： James W. Lillard, JR. , Udai P. Singh , Shailesh Singh , Jonathan K. Stiles
IPC: A61K39/395 , A61P11/06 , A61P19/02 , A61P9/10 , A61P5/14 , A61P17/06 , A61P25/00 , A61P3/10 , A61P29/00 , A61P37/08 , A61K9/00 , A61P11/00
CPC classification number: C07K16/24 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/2866 , C07K16/2896 , C07K2317/76 , C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N2333/521
Abstract: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.
-
10.发明授权Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation 有权抗趋化因子和相关受体抗体以及用于抑制炎症的用途公开(公告)号：US07964194B2
公开(公告)日：2011-06-21
申请号：US10712393
申请日：2003-11-14
Applicant: James W. Lillard, Jr. , Udai P. Singh , Shailesh Singh , Jonathan K. Stiles
Inventor： James W. Lillard, Jr. , Udai P. Singh , Shailesh Singh , Jonathan K. Stiles
IPC: A61K39/00 , A61K39/395
CPC classification number: C07K16/24 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/2866 , C07K16/2896 , C07K2317/76 , C12Q1/6883 , C12Q2600/158 , G01N33/6863 , G01N2333/521
Abstract: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.
Abstract translation: 可以通过给予趋化因子的抗体来抑制炎症过程。 鉴定过度生成的趋化因子使得可以使用针对过度表达的趋化因子的抗体来阻断特异性趋化因子活性。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.016 seconds)
